
OncoDaily Dialogues #1 – Harout Semerjian / Hosted by Roupen Odabashian
We’re thrilled to launch our new series, “OncoDaily Dialogues”. This initiative by OncoDaily is designed to spotlight leaders in the field of oncology, sharing their stories of success, challenges, and life lessons.
For our inaugural dialogue, we’re honored to welcome Harout Semerjian, the President and CEO of GlycoMimetics, as our guest. Mr. Semerjian possesses extensive experience in both biotech and big pharma. He began his career as a pharma representative in Lebanon before ascending to a leadership role at the multinational giant, Novartis. When he departed the company, he held the position of Senior Vice President and Global Launch Lead for Ribociclib. Subsequently, before joining GlycoMimetics, he served as the President and Chief Executive Officer of Immunomedics and as EVP and Chief Commercial Officer of Ipsen. Harout earned his MBAs from Cornell Johnson Graduate School of Management and Queen’s University, and he holds a Bachelor’s degree in Biology from the Lebanese American University.
Our host is Dr. Roupen Odabashian, hematology/oncology fellow at Karmanos Cancer Institute in Detroit, USA. Beyond his clinical practice, Dr. Odabashian possesses an unwavering passion for delving into the intricacies of healthcare policy, regulations and Oncology. He understands the multifaceted nature of cancer as a medical condition and acknowledges the various stakeholders and regulatory bodies that influence the delivery and administration of Cancer treatments. In alignment with this commitment, he has joined OncoDaily, where he plays a pivotal role in conducting interviews with Leaders of the Cancer world.
-
16:39 03/12Rami Manochakian: A special supplement highlighting major data from the IASLC 2023
-
16:28 03/12Jamie Ostroff: A call to action to improve the widespread adoption of smoking cessation guidelines in cancer care
-
16:18 03/12Karen Merritt: The tragic story of Dr. Anil Kapoor who died after one dose of 5FU, just like my mother
-
16:14 03/12Mark Storey: From asymptomatic to oligo, we remain a critical component of treatment
-
15:51 03/12Ishwaria Subbiah: Interesting new study published in the JCO CCI evaluates the utility and privacy of synthetic breast cancer clinical trial data sets
-
16:34 03/12Tedros Adhanom Ghebreyesus: Grateful to Namibia’s Prime Minister Saara Kuugongelwa-Amadhila for her commitment to health
-
18:08 02/12100 Influential Celebrities in Oncology: The 2023 Edition – Part 5
-
16:50 02/12Mara Antonoff: When your famous friends come back to visit their humble beginnings
-
16:12 02/12Nirmala Bhoo Pathy: To all the working mothers out there
-
07:43 02/12Nagashree Seetharamu: What’s in your he(ART)?
-
16:43 02/12In our recent survey, nearly 1,700 ASCO members shared feedback on the ABIM MOC requirements - ASCO
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
17:33 02/12Leukaemia and Myeloma Research UK awarded grants to Neil Rodrigues and Concetta Bubici
-
19:18 01/12Maria Kavallaris has been awarded the prestigious Royal Society of NSW Walter Burfitt Prize for 2023 - Children's Cancer Institute
-
18:35 01/12Sara Beltrán Ponce: Honored to be awarded the Eleanor Montague Distinguished Resident Award in Radiation Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College